{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:50:05Z","timestamp":1791820205740,"version":"4.3.4"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jdcr.2026.08.051","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T14:59:32Z","timestamp":1788706772000},"page":"90-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sustained multisite response to anifrolumab in refractory Chilblain lupus erythematosus"],"prefix":"10.1016","volume":"77","author":[{"given":"Sarah","family":"John","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisabeth V.","family":"Scalzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galen","family":"Foulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2387-7393","authenticated-orcid":false,"given":"Matthew","family":"Helm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2026.08.051_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-201165","article-title":"Chilblain lupus erythematosus","volume":"2013","author":"Patel","year":"2013","journal-title":"BMJ case Rep"},{"issue":"6","key":"10.1016\/j.jdcr.2026.08.051_bib2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bjd.20707","article-title":"Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak","volume":"185","author":"Frumholtz","year":"2021","journal-title":"The Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2026.08.051_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2023.02.044","article-title":"Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus","volume":"89","author":"Chasset","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2026.08.051_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11926-020-00896-6","article-title":"New criteria for lupus","volume":"22","author":"Aringer","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"10.1016\/j.jdcr.2026.08.051_bib5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.0022-202X.2005.23889.x","article-title":"The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus","volume":"125","author":"Albrecht","year":"2005","journal-title":"The J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jdcr.2026.08.051_bib6","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/jid.2013.496","article-title":"Deregulated type I IFN response in TREX1-associated familial chilblain lupus","volume":"134","author":"Peschke","year":"2014","journal-title":"The J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2026.08.051_bib7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter","year":"2023","journal-title":"The Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2026.08.051_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/JW9.0000000000000234","article-title":"Anifrolumab for refractory chilblain lupus erythematosus","volume":"11","author":"Bulosan","year":"2025","journal-title":"Int J women's Dermatol"},{"key":"10.1016\/j.jdcr.2026.08.051_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jdcr.2023.10.020","article-title":"Anifrolumab for the treatment of refractory chilblain lupus erythematosus","volume":"48","author":"Woodbury","year":"2023","journal-title":"JAAD case Rep"},{"key":"10.1016\/j.jdcr.2026.08.051_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.70529","article-title":"Anifrolumab for lupus erythematosus in real-world practice: a Spanish national series","author":"Muntaner-Virgili","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626005229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626005229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:27:23Z","timestamp":1791818843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626005229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":10,"alternative-id":["S2352512626005229"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.08.051","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained multisite response to anifrolumab in refractory Chilblain lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.08.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}